IL4R and Alzheimer disease: We assessed the immunosuppressive activity of ucenprubart in a humanized mouse model of oxazolone-induced delayed hypersensitivity on mouse ears and compared it to an approved AD agent, dupilumab (anti-IL-4 receptor α [anti-IL-4Rα]).